차세대 암 진단 시장 : 제품 유형별, 기술별, 암 유형별, 검체별, 용도별 예측(2026-2032년)

The Next-Generation Cancer Diagnostics Market is projected to grow by USD 37.05 billion at a CAGR of 11.26% by 2032.

Next-generation cancer diagnostics are redefining oncology by moving detection, tumor classification, therapy selection, and recurrence monitoring closer to real-time clinical decision-making. The field spans liquid biopsy, next-generation sequencing (NGS), digital pathology, multiplex immunohistochemistry, minimal residual disease (MRD) testing, companion diagnostics, and AI-enabled interpretation. Demand is supported by a clear disease burden: the International Agency for Research on Cancer reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with new cancer cases projected to exceed 35 million by 2050.

For diagnostic developers and advanced laboratory networks, leadership increasingly depends on analytical validity, clinical utility, reimbursement evidence, and scalable data infrastructure. Oncology stakeholders are prioritizing tests that can shorten diagnostic odysseys, identify actionable biomarkers, guide targeted therapy, and support longitudinal monitoring without overburdening clinicians or health systems.

Transformative Shifts in the Diagnostic Landscape

The cancer diagnostics landscape is shifting from single-analyte, tissue-dependent testing toward integrated multi-omic and longitudinal models. Liquid biopsy is gaining relevance for patients with limited tissue availability, while comprehensive genomic profiling is increasingly used to identify rare but actionable alterations across tumor types. Digital pathology is also moving from workflow digitization to computational assessment of morphology, immune contexture, and biomarker expression.

Regulation and evidence expectations are rising in parallel. The European Union In Vitro Diagnostic Regulation has tightened requirements for clinical evidence and post-market surveillance, while the U.S. FDA's 2024 final rule on laboratory-developed tests signals greater oversight of high-complexity diagnostics. These shifts favor organizations that can combine assay innovation with quality systems, clinical validation, cybersecurity, and transparent performance reporting.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the cancer diagnostics value chain rather than a single point solution. In pathology, AI can support slide triage, mitosis detection, tumor segmentation, and quantitative biomarker assessment. In genomics, machine learning helps classify variants, prioritize molecular findings, and integrate genomic results with clinical phenotypes. In imaging and radiomics, AI can assist lesion detection, risk stratification, and treatment response assessment when appropriately validated.

The impact is strongest when AI is embedded into governed workflows with human oversight. Diagnostic leaders must address model drift, bias, data provenance, explainability, and interoperability with laboratory information systems and electronic health records. Regulatory-grade AI will depend on diverse training datasets, prospective validation, continuous performance monitoring, and compliance with privacy requirements such as HIPAA and GDPR.

Key Regional Insights Across Major Markets

Asia-Pacific is one of the most dynamic regions for next-generation cancer diagnostics, supported by high cancer incidence, expanding sequencing capacity, and national precision medicine programs in China, Japan, South Korea, Australia, and India. China and India present large-volume adoption opportunities but require localization strategies around affordability, reimbursement, hospital access, and regulatory pathways. Japan, South Korea, and Australia are more mature in genomic oncology adoption, quality accreditation, clinical guideline integration, and research-linked implementation.

North America remains a global innovation hub due to advanced oncology networks, FDA-authorized diagnostics, payer activity, clinical trial infrastructure, and strong biopharma investment. Europe is shaped by EU IVDR implementation, national health technology assessment, cancer screening programs, and data protection rules that influence commercialization and evidence requirements. Latin America, the Middle East, and Africa show growing demand for earlier cancer detection and precision oncology, but adoption is uneven due to infrastructure gaps, specialist shortages, laboratory concentration in major cities, and variable reimbursement coverage.

Key Group Insights Shaping Adoption

ASEAN markets are expanding access to oncology testing through public-private hospital investment, regional reference laboratories, medical tourism hubs, and cross-border testing models, though affordability and out-of-pocket spending remain major determinants of uptake. The GCC is investing in genomic medicine, tertiary cancer centers, population health programs, and digital health infrastructure, creating opportunities for high-value molecular diagnostics aligned with national health transformation agendas. The European Union is important for standardized quality expectations, cross-border regulatory harmonization, and evidence-based adoption, but compliance with IVDR and GDPR raises the bar for market entry.

BRICS countries represent scale, local manufacturing potential, and increasing demand for cost-effective precision oncology across diverse healthcare systems. G7 markets provide the strongest evidence, reimbursement, regulatory, and clinical guideline benchmarks for premium diagnostic platforms. NATO markets overlap heavily with high-income healthcare systems where cybersecurity, supply chain resilience, laboratory continuity, and trusted data exchange are increasingly relevant to laboratory modernization, digital pathology, and AI-enabled diagnostics.

Key Country Insights for Precision Oncology

The United States leads in clinical trial density, companion diagnostic development, digital pathology adoption, and commercialization of advanced oncology testing, although payer coverage and evidence requirements remain decisive. Canada emphasizes publicly funded evaluation, provincial reimbursement decisions, and equitable access, while Mexico and Brazil show rising demand through private oncology networks and expanding molecular testing capacity. In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national reimbursement pathways, cancer plans, biomarker testing guidelines, and centralized or regional laboratory models, while Russia faces access, import, and supply constraints that can affect availability of advanced molecular platforms.

In Asia-Pacific, China is scaling domestic sequencing, oncology innovation, and hospital-based molecular testing; India is expanding affordable diagnostics across a large patient base with growing use of NGS and liquid biopsy in metropolitan centers; and Japan supports mature precision oncology pathways through regulated genomic profiling and strong clinical adoption in specialized centers. South Korea combines digital health strength with advanced hospital systems and high oncology research intensity, while Australia benefits from robust research networks, cancer registries, public health infrastructure, and quality-led implementation of genomic testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically actionable indications where next-generation cancer diagnostics can demonstrate measurable impact on treatment selection, time to diagnosis, trial enrollment, or recurrence monitoring. Evidence packages should include analytical performance, clinical validity, clinical utility, health-economic value, and real-world outcomes across diverse populations. Partnerships with cancer centers, pathology networks, biopharma organizations, and payers can accelerate adoption when evidence generation is built into deployment.

Operationally, organizations should invest in interoperable platforms, sample logistics, laboratory automation, quality management systems, and secure data governance. AI-enabled diagnostics require prospective validation, bias testing, workflow integration, model monitoring, and clear clinician-facing outputs. Regional commercialization should be tailored to reimbursement maturity, regulatory expectations, data privacy rules, and local testing infrastructure rather than relying on a single global launch model.

Research Methodology

A robust research methodology for next-generation cancer diagnostics combines secondary intelligence, primary validation, and structured evidence synthesis. Secondary research should include peer-reviewed literature, clinical guidelines, regulatory databases, cancer registry data, reimbursement decisions, patent activity, and public health datasets from organizations such as WHO, IARC, FDA, EMA, CDC, and national oncology agencies.

Primary research should validate adoption barriers, pricing dynamics, test utilization, workflow needs, and procurement priorities through interviews with oncologists, pathologists, molecular laboratory directors, payers, regulatory specialists, and industry executives. Findings should be triangulated across test utilization patterns, installed laboratory capacity, cancer incidence and prevalence patterns, biomarker eligibility, reimbursement status, regulatory pathways, and competitive positioning, with assumptions reviewed for regional variance and data reliability.

Conclusion

Next-generation cancer diagnostics are becoming central to precision oncology, enabling earlier detection, more accurate tumor characterization, targeted therapy selection, and longitudinal disease monitoring. The strongest opportunities will favor organizations that unite scientific credibility, scalable laboratory operations, regulatory readiness, payer-aligned evidence, and secure data infrastructure.

As cancer incidence rises globally, the industry will increasingly reward diagnostics that are actionable, affordable, reproducible, and integrated into clinical workflows. Organizations that combine multi-omic innovation with AI governance, regional commercialization discipline, and real-world evidence generation will be best positioned to shape the future of cancer care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Next-Generation Cancer Diagnostics Market, by Product

• 7.1. Instruments
  • 7.1.1. Analyzers
  • 7.1.2. Sequencers
• 7.2. Reagents & Consumables
• 7.3. Software & Services

8. Next-Generation Cancer Diagnostics Market, by Technology

• 8.1. DNA Microarrays
• 8.2. Lab-on- a- chip & Reverse Transcriptase-PCR
• 8.3. Next-generation Sequencing
• 8.4. Protein Microarrays
• 8.5. qPCR & Multiplexing

9. Next-Generation Cancer Diagnostics Market, by Cancer Type

• 9.1. Breast Cancer
• 9.2. Colorectal Cancer
• 9.3. Lung Cancer
• 9.4. Prostate Cancer

10. Next-Generation Cancer Diagnostics Market, by Sample Type

• 10.1. Blood-Based Samples
• 10.2. Tissue Biopsy

11. Next-Generation Cancer Diagnostics Market, by Application

• 11.1. Cancer Screening
• 11.2. Companion Diagnostics
• 11.3. Prognostics
• 11.4. Risk Assessment
• 11.5. Therapeutic Monitoring

12. Next-Generation Cancer Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Next-Generation Cancer Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Next-Generation Cancer Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Adaptive Biotechnologies Corporation
• 16.3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
• 16.4. Agilent Technologies, Inc.
• 16.5. Akadeum Life Sciences
• 16.6. Almac Group
• 16.7. Becton, Dickinson & Company
• 16.8. Bio-Techne Corporation
• 16.9. Biological Dynamics Inc.
• 16.10. BioNTech SE
• 16.11. Castle Biosciences Inc.
• 16.12. Danaher Corporation
• 16.13. Exact Sciences Corporation
• 16.14. F. Hoffmann-La Roche Ltd.
• 16.15. GE HealthCare
• 16.16. Hologic Inc.
• 16.17. Illumina, Inc.
• 16.18. Johnson & Johnson Services, Inc.
• 16.19. Konica Minolta, Inc.
• 16.20. Koninklijke Philips N.V.
• 16.21. NeoGenomics Laboratories
• 16.22. Novartis AG
• 16.23. OPKO Health, Inc.
• 16.24. Oxford Nanopore Technologies Limited
• 16.25. Qiagen N.V.
• 16.26. Revvity, Inc.
• 16.27. Siemens Healthineers AG
• 16.28. Sysmex Corporation
• 16.29. Telerad Tech
• 16.30. Thermo Fisher Scientific, Inc.